Navigation Links
Over 60 Firms Confirmed to Attend CBI's Third Annual Bio/Pharmaceutical Collaboration and Transaction Accounting Conference in September

BOSTON, Aug. 27 /PRNewswire/ -- The Center for Business Intelligence (CBI), a division of Advanstar Communications, is pleased to announce their full agenda for the 3rd Annual Bio/Pharmaceutical Collaboration and Transaction Accounting. Over 60 firms are already confirmed to gather in Philadelphia on September 22nd for this one-day seminar to hear expert insights and discuss industry case examples for accounting for collaborations and transactions. Perspectives on FASB, IFRS and US GAAP, plus updates on the impact of EITF 07-1, EITF 99-19, EITF 00-21, EITF 07-3 and EITF 08-A will be presented.

The FASB and SEC are considering refinements to the collaboration accounting model. This, coupled with the trend of IFRS convergence, make it critical that life science companies master the financial accounting and reporting of deal-making activities. Amidst changing regulations, top executives from companies such as Goldman Sachs, FASB, GlaxoSmithKline, Infinity Pharmaceuticals and Johnson & Johnson will examine:

  • Recent Mergers and Acquisitions Impacting the Pharmaceutical Sector
  • Examples of Exotic Financings in Life Sciences
  • Trends in Deal Values and Economic Factors in Assessing and Valuing Innovation
  • Milestones and Revenue Arrangements with Multiple Deliverables
  • EITF Updates on Revenue Recognition and Capitalization of Milestone Payments
  • Considerations from a JFC Perspective for Joint Steering Committees (JSCs) and Other Joint Collaboration Meetings
  • FASB Accounting Guidelines for Collaborative Arrangements and Revenue Recognition

If you would like to view the full agenda, please visit this page. A "best-in-class" reputation, CPE credits and professional networking make this an extremely worthwhile event. For more information on this event, please visit If you would like to apply for a press pass, please contact Erica Kirwan of CBI at 339.298.2263.

About CBI:

A subsidiary of Advanstar Communications, CBI Research, Inc. offers Pharmaceutical and Healthcare conferences that serve senior executives and government officials by providing a unique platform for highly focused content and ideal networking opportunities with senior policy- and decision-makers. CBI events provide you with concrete, real-life examples that you can begin to apply at your organization immediately for significant impact on costs and revenue. For more information, please visit

This release was issued through eReleases(TM). For more information, visit

SOURCE Center for Business Intelligence
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
2. Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts
3. Independent U.S. Study Confirms Veritides Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability
4. Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize
5. Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010
6. NIH News Confirms Trend in Stem Cell Storage Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group
7. GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
8. Mylan Confirms Four First-to-File Challenges
9. Gentag, Inc. Engages US and UK Firms to Explore Strategic Options
10. Three Firms, Two Training Programs Garner Greater Baltimore Committees 2009 Bioscience Awards
11. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
Post Your Comments:
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... , November 26, 2015 ... device company specializing in imaging technologies, announced today that it ... as part of the Horizon 2020 European Union Framework Programme ... a large-scale clinical trial in breast cancer. , ... , --> --> The ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
Breaking Biology News(10 mins):